Literature DB >> 33422500

Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen.

Seigo Kimura1, Ikramy A Khalil2, Yaser H A Elewa3, Hideyoshi Harashima4.   

Abstract

This study reports on the development of a novel lipid combination that permits the efficient and highly selective delivery of plasmid DNA (pDNA) to immune cells in the spleen. Using DODAP, an ionizable lipid that was previously thought to be inefficient for gene delivery, we show for the first time, that this ignored lipid can be successfully used for efficient and targeted gene delivery in vivo, but only when combined with DOPE, a specific helper lipid. Using certain DODAP and DOPE ratios resulted in the formation of lipid nanoparticles (LNPs) with a ~ 1000-fold higher gene expression, and this expression was specific for the spleen, making it the most spleen-selective system for transfection using pDNA. The developed DODAP/DOPE-LNPs target immune cells in the spleen via receptors for complement C3 and this pathway is critical for efficient gene expression. We hypothesize that the high spleen transfection activity of DODAP/DOPE-LNPs is caused by the promotion of gene expression associated with B cell activation via complement receptors. LNPs encapsulating tumor-antigen encoding pDNA showed both prophylactic and therapeutic anti-tumor effects. The optimized LNPs resulted in the production of different cytokines and antigen-specific antibodies as well as exerting antigen-specific cytotoxic effects. This study revives the use of DODAP in gene delivery and highlights the importance of using appropriate lipid combinations for delivering genes to specific cells.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immune cell; Ionizable lipid; Nanoparticle; Plasmid; Spleen; Vaccine

Year:  2021        PMID: 33422500     DOI: 10.1016/j.jconrel.2021.01.005

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

Review 1.  Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.

Authors:  Lanying Du; Yang Yang; Xiujuan Zhang; Fang Li
Journal:  Nanoscale       Date:  2022-01-27       Impact factor: 7.790

Review 2.  A review of the tortuous path of nonviral gene delivery and recent progress.

Authors:  Divya Sharma; Sanjay Arora; Jagdish Singh; Buddhadev Layek
Journal:  Int J Biol Macromol       Date:  2021-06-01       Impact factor: 8.025

Review 3.  The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery.

Authors:  Ruvanthi N Kularatne; Rachael M Crist; Stephan T Stern
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-20

4.  Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study.

Authors:  Alexander Meleshko; Nadzeya Piatrouskaya; Katsiaryna Vashkevich; Dzmitry Lutskovich; Chuan Wang; Dmitri Dormeshkin; Natalia Savelyeva; Mikalai Katsin
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

5.  mRNA-Loaded Lipid Nanoparticles Targeting Immune Cells in the Spleen for Use as Cancer Vaccines.

Authors:  Ryoya Shimosakai; Ikramy A Khalil; Seigo Kimura; Hideyoshi Harashima
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-18

Review 6.  Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.

Authors:  Saed Abbasi; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.